Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

OCTOBER 2025

Molecular pathology selected abstracts

October 2025—GATA2 deficiency is a rare inherited condition that disrupts the normal development of blood and immune cells. People born with this genetic disorder may experience low blood counts, frequent infections, or such problems as lymphedema and hearing loss. The most serious long-term risk is development of myelodysplastic syndrome (MDS), a bone marrow disorder that can progress to leukemia. The authors conducted a large study in which they followed 218 people with confirmed GATA2 mutations to understand when and how MDS develops. In this cohort, symptoms of GATA2 deficiency were present in 205 of the participants, of whom 187 (91.2 percent) had MDS.

Pathology informatics selected abstracts

October 2025—Large language models are becoming commonplace for personal and business use. The health care community is leveraging large language models (LLMs) for various purposes. Researchers at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, have successfully used open-source LLMs to extract critical medical data from pathology reports. They conducted a study that demonstrated how LLMs can transform unstructured clinical text into structured pathology data. While pathology reports are rich in information about tumor type, size, and stage, their narrative format makes automated data extraction difficult.

Newsbytes

October 2025—For pathology residents, there are easier tasks than writing a perfect preliminary case report on the first attempt. Nailing Jell-O to a tree, for example, or stapling sunlight to a cloud. “When the attendings make no changes or just sign out the case as we wrote it, there’s a sense of accomplishment,” says Jingjing Cao, MD, pathology resident in the Departments of Pathology and Laboratory Medicine, University of California San Francisco.

Put It on the Board

October 2025—Send-out and other high-cost tests are the typical targets of lab stewardship, but a clinical decision support session at the ADLM meeting in July had a different focus: daily labs. It’s generally believed there is little to no opportunity for savings on daily labs because the reagent cost per test is low, as is the incremental labor savings for tests performed on automated instruments. Instead, said Grace Mahowald, MD, PhD, informatician and director of the core laboratory at Massachusetts General Hospital, “think about what goes into the cost of each of our daily lab tests,” from the nurse, patient care assistant, and phlebotomist to the specimen transporter and the lab receiving staff and technical staff who review results and call providers when specimens have to be refused at receipt. “And it’s questionable if people are even looking at the result,” she said.

Where court’s LDT decision leaves labs

September 2025—The Food and Drug Administration’s efforts to regulate laboratory-developed tests as medical devices came to a decisive halt this spring with a ruling from the U.S. District Court …

How a core lab took back its outpatient business

September 2025—Angela Vetch, MPH, DLM(ASCP), is tired of reading about large commercial labs buying hospital laboratories’ outreach business. “There is an alternative to that story,” said Vetch, director of laboratory services at Kootenai Health, a three-hospital system in Coeur d’Alene, Idaho.

At AMP, latest on self-collection, avian influenza, and more

September 2025—Avian influenza, self-collection, and diagnostic stewardship in the microbiology laboratory are three topics of many that can be explored at the Association for Molecular Pathology meeting in Boston this November. Andrew Pekosz, PhD, heads a research laboratory at Johns Hopkins University that studies the replication and disease potential of emerging respiratory viruses.

AMP case report: Germline variant not present in tumor?

September 2025—A 68-year-old male with a history of multiple myeloma was discovered to have a 3-cm carotid body mass on PET/CT. Surgery was consulted and determined that the lesion was not amenable to surgery. Radiology favored the lesion to be a paraganglioma, so plasma metanephrine and normetanephrine were tested and were negative. With paraganglioma as the working diagnosis, germline genetic testing was performed.

Layers of evaluation in thyroid carcinoma diagnosis

September 2025—In a CAP session last year on timely topics in thyroid tumors, Zubair W. Baloch, MD, PhD, shed light on poorly differentiated and differentiated high-grade follicular-derived carcinomas. “This is something new in the WHO 5th edition of the thyroid tumor classification scheme, and I think it’s about time that we have a different category and not really split them too much,” said Dr. Baloch, an editor and author of the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. Why the category is new and what to know was part of the timely topics session, for which he paired up with Nikolina Dioufa, MD, PhD, MSc, who spoke about noninvasive follicular thyroid neoplasm with papillary-like nuclear features and follicular variant of papillary thyroid carcinoma.

MARKETPLACE

TRENDING